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RaftLike all other monomeric or multimeric transmembrane proteins, receptors for neurotransmitters are
surrounded by a shell of lipids which form an interfacial boundary between the protein and the bulk
membrane. Among these lipids, cholesterol and sphingolipids have attracted much attention because of their
well-known propensity to segregate into ordered platform domains commonly referred to as lipid rafts. In
this review we present a critical analysis of the molecular mechanisms involved in the interaction of
cholesterol/sphingolipids with neurotransmitter receptors, in particular acetylcholine and serotonin
receptors, chosen as representative members of ligand-gated ion channels and G protein-coupled receptors.
Cholesterol and sphingolipids interact with these receptors through typical binding sites located in both the
transmembrane helices and the extracellular loops. By altering the conformation of the receptors
(“chaperone-like” effect), these lipids can regulate neurotransmitter binding, signal transducing functions,
and, in the case of multimeric receptors, subunit assembly and subsequent receptor trafﬁcking to the cell
surface. Several sphingolipids (especially gangliosides) also exhibit low/moderate afﬁnity for neurotrans-
mitters. We suggest that such lipids could facilitate (i) the attachment of neurotransmitters to the post-
synaptic membrane and in some cases (ii) their subsequent delivery to speciﬁc protein receptors. Overall,
various experimental approaches provide converging evidence that the biological functions of neuro-
transmitters and their receptors are highly dependent upon sphingolipids and cholesterol, which are active
partners of synaptic transmission. Several decades of research have been necessary to untangle the skein of a
complex network of molecular interactions between neurotransmitters, their receptors, cholesterol and
sphingolipids. This sophisticated crosstalk between all four distinctive partners may allow a ﬁne biochemical
tuning of synaptic transmission.
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Lipids are the most abundant organic compounds found in the
brain, accounting for up to 50% of its dry weight [1]. As in other
mammalian tissues, brain lipids consist mainly of three major
categories: glycerophospholipids, sphingolipids and cholesterol [2].
Most of these lipids are part of membrane structures. Since the
original formulation of the mosaic ﬂuid model by Singer and Nicolson
[3], it has become evident that the role of membrane lipids is not just
to provide a bidimensional solvent for membrane proteins: they are
also involved in key biological functions linked to the spatial
organization of the cells, e.g., cellular adhesion [4], toxin and pathogen
attachment [5], signal transduction [6] or protein trafﬁcking [7].
Sphingolipids and cholesterol, which coalesce and form ordered
platform domains (commonly referred to as lipid “rafts”) that are
segregated from the bulk membrane, are privileged actors of these
critical processes. The biochemical composition, biophysical proper-
ties, detergent solubility and biological functions of these lipid
domains have been analyzed and discussed in several excellent
reviews [8–13]. Despite these synthetic efforts, one fundamental issue
warrants further consideration: proteins that are associated with lipid
domains might be surrounded by a shell of typical raft lipids
(sphingolipids, cholesterol) which mediates the transfer of the protein
from the bulkmembrane to the domain [7]. This lipid shell or annulus is
analogous to the layer of solvent (water) molecules surrounding
soluble proteins: in both cases, a rigid layer of tightly bound solvent
molecules separates the protein from the bulk solvent. What are the
biochemical mechanisms and the molecular forces involved in these
lipid–protein interactions? To what extent are they speciﬁc? What is
the impact of these interactions on the conformation and further on the
functional activity of the proteins? Sphingolipids were discovered in
the brain more than one century ago [14], but their functions in neural
tissues are far from being understood [15]. Nevertheless, a growing
body of data suggests that sphingolipids and/or cholesterol are
indispensable partners of neurotransmitter receptor conformation,
function and trafﬁcking. The scope of this review is to bring together
thesedata and to propose a generalmodel accounting for thismajor but
generally underappreciated function of domain-forming lipids. To
remain concise and comprehensive, our discussion will be mainly
focused on acetylcholine and serotonin receptors, i.e., two key
members of the Cys-loop superfamily of ligand-gated ion channels
(nicotinic acetylcholine receptor, 5-HT3 serotonin receptor) as well as
representativemembers of Gprotein-coupled receptors (5-HT1, 5-HT2,
5-HT4, 5-HT5, 5-HT6 and 5-HT7 serotonin receptors).
2. Sphingolipids in neural tissues: historical ﬁndings, current
status and perspectives
The history of sphingolipids begins at the end of the nineteenth
century when J.L.W. Thudichum discovered a group of glycosidic
substances in brain, composed of three building blocks: a fatty acid, a
long chain base, and a hexose [14]. Thudichum coined the word‘sphingosine’ to designate the long-chain base ‘in commemoration of
the many enigmas which it presented to the inquirer,’ in reference to
the Sphinx enigmas of Greekmythology. Early investigators identiﬁed
it as di-hydroxyamino-octadecene, but the relative position of the
functional groups remained uncertain until Carter and co-workers
reported the correct structure in 1947 [16]. Interestingly, and contrary
to a widespread extrapolation [17], the term ‘sphingolipid’ was not
invented by Thudichum, but by Carter et al. who proposed to give the
name ‘sphingolipides’ to all lipids derived from sphingosine [18]. In
1958, Shapiro et al. published the total synthesis of sphingosine,
conﬁrming its chemical structure as trans-D-erythro-1,3-dihydroxy-
2-amino-4-octadecene (or, according to the R/S system, trans-
(2S,3R)-1,3-dihydroxy-2-amino-4-octadecene [19] (Fig. 1). Subse-
quently it appeared that even though sphingosine is by far the main
sphingoid base found inmammals, a number of other derivatives such
as sphinganine (i.e., sphingosine without the trans-C4–C5 double
bond) and phytosphingosine (C4–OH sphinganine) have also been
detected [20,21]. Correspondingly, the deﬁnition of sphingolipids as
sphingosine-derived lipids [18] has been tacitly extended to all lipids
derived from sphingosine and structurally related sphingoid bases.
Sphingolipids exhibit a huge heterogeneity in their structure [22]. The
nature of the sphingoid base is the ﬁrst level of biochemical diversity
in sphingolipids. The second level is provided by the numerous fatty
acids (more than 20, varying in chain length, degree of saturation, and
degree of hydroxylation) that can be attached to the sphingoid base to
form a ceramide (Fig. 1). The third level of diversity corresponds to
the polar group linked to ceramide, whose chemical structure
determines the sphingolipid classiﬁcation: phosphorylcholine for
sphingomyelins (SM), or a glycone moiety for glycosphingolipids
(GSLs). The structures shown in Fig. 1 illustrate how distinct in shape
these sphingolipids can be. Several hundreds of different carbohy-
drate structures have been described in GSLs, which, by combining the
three levels of diversity described above, comprise thousands of
biochemically distinct molecules [23]. GSLs can be either neutral or
electrically charged at pH 7. Neural tissues contain sulfated GSLs
(sulfatides) and sialic acid-containing GSLs (gangliosides) both
negatively charged [1], but also several types of cationic GSLs [24]
(Fig. 1). In the central and peripheral nervous system, the most
abundant neutral GSL is galactosylceramide (GalCer), which accounts
for as much as 24% of myelin [25]. The sulfated congener of GalCer
(galactosylsulfatide, i.e., 3′-sulfoGalcer), generally referred to as
sulfatide, is also present in the myelin sheath (4%). Studies with
knock-out mice suggested that both GSLs play important roles in
myelin function and stability [26]. Gangliosides, the sialic acid-
containing GSLs, were both isolated and named by Klenk in 1942
[27]. The main gangliosides in the mammalian central nervous system
are GM1, GD1a, GD1b, and GT1b, which together account for 80–90%
of the total gangliosides [1]. Their concentration in the extracellular-
facing monolayer of neural plasma membranes has been estimated to
be 10–20% of the total membrane lipid [25]. Gangliosides have been
implicated in major neural functions including brain development,
neuritogenesis, memory formation, synaptic transmission, and aging
Fig. 2. Chemical structure of cholesterol with special emphasis of its bifacial geometry.
(A) Structure of cholesterol with numbering of the carbon atoms. If we follow the order
of carbon numeration of the ﬁrst cycle, we are moving in the anti-clockwise direction
which deﬁnes the beta face, according to the nomenclature proposed by I.A. Rose for
cyclic compounds [35]. (B) Global shape of the cholesterol molecule, with a smooth face
devoid of substituents (alpha) and a rough face (beta) with two methyl groups and the
iso-octyl chain. (C) Space-ﬁlling model of cholesterol.
Fig. 1. Diversity of sphingolipid structures. Chemical structure of sphingosine (upper
left): according to the Fisher convention, the amino group on the right side of the
carbon chain (D series) and the two OH groups on the same side (erythro
conﬁguration) explain why the molecule is referred to as D-erythro-sphingosine. Yet
this representation does not ﬁt with the more realistic conformation of sphingosine
shown on the right (minimum energy conformer simulated in vacuo with the Polak–
Ribiere algorithm of the Hyperchem software). The other sphingolipid structures have
also been obtained bymolecular modelling simulations in vacuo. The ceramide contains
an alpha-hydroxylated acyl chain (ceramide-HFA).
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tissues, one should also mention the existence of cationic GSLs, such
as de-N-acetyllactotriaosylceramide (GlcNH2β1-3Galβ1-4GlcCer or
de-Nacetyl-Lc3Cer) (Fig. 1). This singular GSL has been puriﬁed
relatively recently from bovine brain white matter by Hakomori and
co-workers [29]. These authors suggested that such cationic GSLs
could affect the organizational assembly of GSLs in the membrane,
which are almost all either anionic or neutral, resulting in perturba-
tions of signal transduction. This opens an attractive and rather
unexpected new avenue in brain research which warrants further
experimental examination.
3. Cholesterol: the bifacial lipid
Cholesterol is the privileged lipid partner of sphingolipids in
membrane microdomains. In the nervous system, cholesterol is also
the main lipid component of myelin (28%) [25]. The structure of
cholesterol is shown in Fig. 2. The biochemistry, physical properties
and functions of cholesterol in relation to sphingolipid association and
lipid domain formation have been the subject of excellent experi-
mental studies and reviews [10,30–34], andwewill therefore focus on
speciﬁc structural features directly related to the scope of the present
article. Perhaps the most widely ignored structural property of
cholesterol is that it is a dissymmetrical molecule with two distinctfaces, one smooth and the other rough due to the methyl substituents
of carbons C10 and C13, and the iso-octyl chain linked to C17.
According to the alpha/beta-face system numeration of ring com-
pounds proposed by Rose et al. [35], the planar smooth face of
cholesterol is referred to as the alpha face, the opposite rough side
being the beta face (see legend of Fig. 2 for explanation). This
topological dissymmetry allows one molecule of cholesterol to
interact with two distinct membrane molecules, e.g., a sphingolipid
through the alpha face [36] and a transmembrane protein through the
beta face [37]. This unique biochemical feature of cholesterol will be
further discussed below (see Fig. 11).
4. Neurotransmitters, sphingolipids, cholesterol and receptors:
from molecular interactions to physiological regulation
4.1. Bidimensional concentration of neurotransmitters through binding
to cell surface GSLs
Synaptic vesicles contain very high concentrations of neurotrans-
mitters (up to 600mM), thus favouring the formation of non-covalent
oligomers (aggregates) as demonstrated for serotonin [38]. Upon
release of the vesicles' content in the synaptic space, the neurotrans-
mitter concentration is suddenly decreased such that monomers are
spontaneously released from the aggregates. To exert its biological
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where it binds to its target receptor, a protein macromolecule. The
transfer of neuromediator molecules from a three-dimensional space
(the synaptic space) to a two-dimensional one (the post-synaptic
membrane) results in a further increase in neurotransmitter concen-
tration through a typical mechanism of reduction in dimensionality
[39]. It has been known for many years that neurotransmitters such as
serotonin bind to several gangliosides known to be present on neural
cell membranes [40,41]. In fact, these GSLs had been considered for
quite some time to be part of the neurotransmitter receptors, a
hypothesis that was deﬁnitively abandoned once the real protein
receptors were identiﬁed and characterized. Nevertheless, it is still
reasonable to assume that the low afﬁnity binding of neurotransmit-
ters to acidic GSLs [42] is an efﬁcient way to ‘catch’ neurotransmitters
onto the postsynaptic membrane (i.e., a concentrating effect) and also
to prevent their aggregation. This scenario has been visualized for
serotonin (Fig. 3). Molecular dynamics simulations were conducted to
ﬁgure out the possible effects of the ganglioside on the bioavailability
of serotonin in the vicinity of the post-synaptic membrane. Our data
suggested that the ganglioside could (i) destabilize serotonin
aggregates and (ii) bind to monomeric serotonin with a low/
moderate afﬁnity. The neurotransmitter molecules that are released
from the aggregates can either bind to a receptor in the post-synaptic
membrane, or be re-captured by the pre-synaptic neuron. On theFig. 3. Putative accessory function of ganglioside binding sites for neurotransmitters on
the post-synaptic membrane. In the synaptic vesicle, the neurotransmitter concentra-
tion is high (up to 600 mM), which favours its aggregation through non-covalent
interactions, as shown for serotonin (5-HT). Upon release in the synaptic cleft, some
aggregates are spontaneously dislocated, whereas others are electrostatically attracted
by the gangliosides (e.g., GM1) present in the post-synaptic membrane. These
gangliosides have two main effects: (i) they contribute to destabilizing neurotrans-
mitter aggregates, and (ii) they can interact with neurotransmitter monomers, through
low/moderate afﬁnity interactions. Eventually, the monomers will reach speciﬁc
protein receptors in the post-synaptic membrane. This concept of a dual GSL/receptor
system for neurotransmitters in the post-synaptic membrane is similar to the double
receptor model developed by C. Montecucco for the binding of neurotoxins to neuronal
membranes [47,48].other hand, the neurotransmitter monomers that interact with the
post-synaptic membrane can be routed and transferred to their high-
afﬁnity protein receptors (Fig. 3).
In addition to serotonin [40–43], both GABA and glutamate have
been reported to interact with sulfatide as well as various phospho-
lipids including sphingomyelin [44]. Peptidic neurotransmitters such
as leucine enkephalin, alpha-MSH and substance P have also been
shown to interact with GSLs [45,46], suggesting that binding to cell
surface sphingolipids might be a general property of neurotransmitter
molecules. As pointed out by Montecucco in his double-receptor
model [47,48], a similar strategy based on the cooperation of
gangliosides and protein receptors seems to be used by neurotoxins
such as the botulinum toxin to achieve optimal binding to neural cells.
4.2. Regulation of receptor function by gangliosides
In aqueous solution, gangliosides form micelles which, upon
incubation with cell or tissue cultures, can transfer these charged
GSLs to the plasma membrane of recipient cells [49]. Several
researchers have taken advantage of this property to appreciate
ganglioside action in the nervous system by (i) adding gangliosides to
neurons in culture, or (ii) treating animals during neuronal regener-
ation [50]. This made it possible to demonstrate that ganglioside GM1
enhances neurite outgrowth in PC-12 cells, through NGF and integrin-
dependent mechanisms [51,52]. Overall, gangliosides were found to
increase the rate and extent of sprouting of regenerating axons and
enhance neuronal differentiation and sprouting in vitro and in vivo
[50]. Direct effects of gangliosides on receptor function have also been
characterized. In particular, gangliosides GM1 and GQ1b have a
marked stimulatory effect on the functional coupling between
adenylate cyclase and serotonin receptors [53]. Similarly, GM1
treatment of cultured neurons was reported to induce an increased
efﬁcacy of excitatory opioid receptor-mediated Gs activation [54]. This
has led to the striking conclusion that GM1 could contribute to opioid
tolerance and dependence by regulating the excitatory signalling of G-
coupled opioid receptors [55]. Indeed, decreasing neuronal levels of
GM1with a neuraminidase inhibitor blockedmorphine's hyperalgesic
effects in mice. Overall, these data demonstrate that the functional
activity of representative neurotransmitter receptors can be regulated
by exogenous gangliosides and, in some cases, by pharmacological
alteration of endogenous ganglioside content. Does this mean that
endogenous gangliosides are intimately associated with neurotrans-
mitter receptors and that these membrane sphingolipids can affect
their signalling properties? Such a simple interpretation of the data
obtained with exogenously added ganglioside is not always possible.
Indeed, three modes of interaction between ganglioside micelles and
target cells have been described: (i) weak association with the plasma
membrane (readily washable with saline), (ii) efﬁcient adsorption on
membrane proteins (removed by proteolytic digestion), and (iii)
stable insertion within the outer leaﬂet of the membrane (protease-
resistant) [49]. As these distinct modes of association may not be
mutually exclusive, this renders difﬁcult the interpretation of the data
obtained with micellar ganglioside solutions. In particular, it may not
be easy to distinguish the effects resulting from an interaction in cis
(ganglioside inserted in the plasmamembrane of the responding cell)
from an interaction in trans (ganglioside bound to but not inserted in
the membrane of the target cell). Ideally, a combination of techniques
including pharmacological modulation of sphingolipid metabolism
[56,57] and/or chemically induced alteration of lipid domain integrity
and functions [58,59] should be used in parallel to treatment with
ganglioside micelles.
4.3. Physical association of GSLs with membrane receptors
Despite the potential caveats discussed above, the concept of a
functional association between GSLs and membrane proteins has
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established that selected GSLs bind to the receptors for tyrothropin
[61], vitronectin [62], insulin [63], EGF [64], PDGF [65], as well as other
growth factors involved in brain tumours [66]. A GSL-mediated
regulation of a neurotransmitter receptor through a molecular
interaction with ganglioside GM1 has been reported for the delta-
type opioid receptor [67,68]. This is in line with the studies showing
that ganglioside GM1 plays a crucial role in regulating excitatory
opioid receptor function, with a marked impact on opioid depen-
dence, tolerance, and supersensitivity [54,55]. This receptor belongs
to the family of G protein-coupled receptors, integral membrane
proteins with sevenmembrane-spanning domains. G protein-coupled
receptors respond to a wide range of stimuli (light, odour, taste) and
chemical agents (neurotransmitters, lipid analogues). Upon ligand
binding, these receptors undergo conformational changes which
trigger the functional coupling of an intracellular domain of the
receptor to a heterotrimeric G protein. The data obtained with CHO
cells transfected with the delta opioid receptor suggested that GM1
induces a conformational change of the opioid receptor from a form
coupled primarily to Gi (inhibiting cAMP production) to one also
capable of interacting with Gs (stimulating cAMP production) [68].
This indicates that the GSLs that bind to such receptors can induce
important alterations in their activity through conformational effects.
In some instances, the afﬁnity of the receptor for the GSLs can be
high enough to resist detergent solubilization and puriﬁcation
procedures [62,69]. When this is the case, it is noteworthy that only
one GSL species is carried along with the receptor during the
puriﬁcation process. Such a high selectivity of the co-puriﬁed GSL
argues against a ‘reminiscence’ of the biochemical composition of the
membrane domain from which the receptor has been extracted.
Instead, these data suggested that GSLs can physically interact with a
subset of membrane receptors, which, in total agreement with the
lipid shell concept [7], segregate into sphingolipid/cholesterol-
enriched microdomains of the plasma membrane. Most of the data
available on sphingolipid-mediated receptor regulation concern GSLs
and chieﬂy gangliosides. Yet, as we will see for the nicotinic
acetylcholine receptor, sphingomyelin can also be a very efﬁcient
modulator of receptor assembly and trafﬁcking [70].
4.4. Effects of cholesterol on receptor function
That cholesterol could, like sphingolipids, regulate the function of
membrane receptors, has been recognized for several years [71].
Cholesterol has been shown tomodulatemembrane receptor function
through two main mechanisms: direct interaction with the receptor
or broad effect on the biophysical properties of the membrane lipid
bilayer [72,73]. In the nervous system, several G protein-coupled
receptors have been particularly well studied for their functional
dependence on cholesterol, e.g., rhodopsin, the photoreceptor of the
rod cell, the receptors for the neuropeptides oxytocin and cholecys-
tokinin, and the receptors of the neurotransmitters acetylcholine and
serotonin. Rhodopsin is a classical G protein-coupled receptor,
activated by light. High cholesterol concentrations were found to
impair the functional light-induced coupling of rhodopsin to
transducin (the rhodopsin-coupled G protein) in reconstituted bilayer
membranes [74]. This effect was attributed to cholesterol modulation
of the properties of the membrane bilayer, resulting in a decrease in
the free volume available for molecular motion in the hydrophobic
core of the bilayer [74]. In addition to this indirect effect, Albert et al.
[75] were able to demonstrate a speciﬁc interaction between
cholesterol and rhodopsin. Taken together, these data raised the
intriguing possibility that the regulatory effects of cholesterol on
rhodopsin activity could involve direct and indirect mechanisms. A
direct interaction with cholesterol has also been demonstrated for the
G protein-coupled receptor for oxytocin, a neurohypophyseal non-
apeptide [76,77]. In contrast, the human cholecystokinin receptorssubtype B did not bind cholesterol but were indirectly affected by the
changes in physical properties associated with modulations of
membrane cholesterol content [78]. These receptors have been
involved in important functions of the nervous system including
analgesia [79] and exploratory behavior [80]. Again, these data
showed that cholesterol could alter brain receptors by two distinct
mechanisms, i.e. physical interaction with the receptor and non-
speciﬁc changes of biophysical membrane properties [72]. The
different mechanisms by which cholesterol could interact with G
protein-coupled receptors have been recently reviewed [81]. In view
of the scope of the present work, we will limit our discussion to those
involved in the regulation of nicotinic acetylcholine and serotonin
receptors by membrane cholesterol.
5. Serotonin receptors
5.1. The serotonin molecule: structural features and binding to
ganglioisides
The chemical structure of serotonin (5-hydroxytryptamine, 5-HT)
[82] is shown in Fig. 4A. It is a nitrogen-containing aromatic cycle
(indole) with a hydroxy substituent in the 5-position on the ring (5-
OH group) and an ethylamine chain with is positively charged at pH 7.
The aromatic structure is primarily responsible for the self-aggrega-
tion properties of serotonin in synaptic vesicles [38]. Molecular
modelling simulations of serotonin aggregates in water showed a
stacked geometry of interaction (Fig. 4B), which is remarkably similar
to other stacking interactions between aromatic compounds (e.g.,
adenine) [83]. The presence of a positive charge on the ethylamine
chain, together with the aromatic cycle, confer on serotonin the ability
to interact with gangliosides [40–43], as shown in Fig. 4C for GM1. In
this molecular model, the CH3 of the N-acetyl group borne by the
sialic acid of GM1 is oriented towards the aromatic ring of serotonin,
consistent with the establishment of a CH–Pi interaction [84].
Moreover, the positive charge of the amino group of serotonin
interacts with the negative charge of the sialic acid residue of GM1.
Overall, the combination of an electrostatic plus a CH–Pi interaction is
consistent with a low to moderate afﬁnity for the serotonin/GM1
complex. Such molecular interactions between serotonin monomers
and GM1 might take place following the release of the neurotrans-
mitter from synaptic vesicles, as described in Fig. 3.
Despite its simple structure, serotonin plays a signiﬁcant role in a
number of fundamental biological processes such as the regulation of
mood, stress, sleep, human sexuality, appetite, and metabolism [85]. A
ﬁrst level of explanation for such pleiotropic effect would be the
occurrence of multiple serotonin conformers able to stimulate distinct
receptors. The ﬂexibility of the ethylamine chain and the multiple
possible orientations of the 5-OH group, which can generate a wide
range of conformations, strongly support this view [86]. One can
hypothesize that upon binding to post-synaptic GSLs, speciﬁc con-
formations of serotonin could be favoured on the basis of GSL structure
(Fig. 4C). If this assumption is correct, GSLs could function asmoulds for
serotonin so that this initial step of binding to the post-synaptic
membrane would become essential for the pre-selection of serotonin
receptor subsets. This would help serotonin to ﬁnd its way in the
intricate network constituted by its numerous membrane receptors.
5.2. Serotonin receptors: an endless complexity
Seven distinct families of serotonin receptors (numbered 5-HT1 to
5-HT7) have been identiﬁed so far, and subpopulations have been
described for several of these [87]. With the exception of the 5-HT3
receptor, a ligand-gated Na+ and K+ cation channel, all other
serotonin receptors are coupled to G proteins. The 5-HT1 and 5-
HT5A subtypes are coupled to Gi (decreasing cAMP levels), whereas
the 5-HT4, 5-HT6 and 5-HT7 are coupled to Gs (increasing cAMP
Fig. 4. Chemical structure of serotonin: from monomers to aggregates. (A) Chemical structure of serotonin. Serotonin is represented as a tube model with carbon numbering (left
panel) or as a spaceﬁll model (right panel). (B) Serotonin aggregates in water. Four molecules of serotonin have been placed in a periodic box with 185 water molecules. Following
geometry optimization with the Polak–Ribiere algorithm, molecular dynamics simulations (MM+ force ﬁeld) were conducted for 1 ps. Two distinct orientations of the periodic box
are shown, both showing the well-organized stacking geometry of the serotonin molecules. (C) Binding of serotonin to GM1: importance of electrostatic and CH–Pi interactions. A
molecular model of serotonin bound to GM1 has been obtained in vacuo with the Hyperchem software. The molecular forces involved in the complex are (i) the CH–Pi interaction
between the CH3 of the N-acetyl group of the sialic acid residue in GM1 and the aromatic cycle of serotonin (yellow disc), and (ii) the electrostatic interaction between the
protonated amino group of serotonin and the anionic carboxylate of the sialic acid (purple dotted line).
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triphosphate and diacylglycerol levels). The complexity of the system
is further expanded by posttranslational modiﬁcations, such as
alternate splicing and RNA editing, oligomerisation, and crosstalk
within and possibly between receptor families [88]. The ultimate
stabilization, functional coupling and crosstalk between serotonin
receptors in the plasma membrane offer multiple regulatory possi-
bilities for cholesterol and sphingolipids, as discussed below.
5.3. G protein-coupled serotonin receptors: structural and functional
links with sphingolipids and cholesterol
A ﬁrst approach to evaluating the functional impact of sphingo-
lipids and/or cholesterol on G protein-coupled serotonin receptors is
to study their association with lipid domains. It is somewhat
surprising that this important issue has not received much attention.
In January 2009, the PubMed query ‘serotonin receptor lipid raft’
retrieved only six articles, compared with 81 for ‘neurotransmitter
receptor lipid raft,’ 799 for ‘receptor lipid raft’ and 2270 for ‘lipid raft.’The following G protein-coupled serotonin receptors have been
unambiguously found in detergent-resistant (“raft”) fractions: 5-
HT1A [89], 5-HT2A [90], and 5-HT7 [91]. The double palmitoylation of
5-HT4 suggests its recruitment in lipid domains [92], as demonstrated
later for 5-HT1A [89]. 5-HT6 interacts with Fyn [93], a member of the
Src family of non-receptor protein-tyrosine kinase known to be
enriched in lipid domains [94]. In addition to these receptors, the
serotonin transporter (SERT) has also been detected in lipid domain
fractions of pre-synaptic membranes [95]. This integral membrane
protein plays a prominent role in the regulation of serotoninergic
neurotransmission and is a molecular target for multiple antidepres-
sants. The simultaneous presence of serotoninwith G protein-coupled
receptors and of serotonin with SERT, in sphingolipid/cholesterol
plasma membrane microdomains, indicates that lipid domains
behave as functional platforms able to coordinate several serotonin
functions in both the pre- and post-synaptic membranes.
The function of several of G protein-coupled receptors has been
shown to be regulated by lipid domains [96]. All the available data
suggest that this is also the case for G protein-coupled serotonin
Fig. 5. A regulatory cassette in the 5-HT1A receptor: location of serotonin and cholesterol
binding sites in the vicinity of the switch for G protein activation. The regulatory unit
includes: (i) the second and third transmembrane helices of 5-HT1A (TM2 and TM3),
which are separated by the second extracellular domain (2nd EL), (ii) the serotonin
binding pocket involving amino acid residues D82 in TM2 and D116 in TM3, (iii) the DRY
triad (D133–R134–Y135) in the second intracellular loop (2nd IL) at the bottom of TM3
which functions as a switch for protein G activation upon serotonin binding, and (iv) the
cholesterol binding motif involving residue Y73 in TM2. The ﬁrst intracellular loop (1st
IL) and the orientation of the peptidic chain of the receptor (N-ter to C-ter) are indicated.
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cholesterol depletion affected both ligand binding activity and G
protein coupling of 5-HT1A receptors in bovine hippocampal
membranes [97]. Mutations of the palmitoylation sites (which control
the association with lipid domains) in mouse 5-HT1A receptors
abolished the functional coupling of these receptors with G proteins
[89,98]. Palmitoylation also plays an important role in modulating
mouse 5-HT4A receptor functions [92]. Reduction in sphingomyelin
and GSLs levels upon treatment with metabolic inhibitors resulted in
decreased serotonin binding to 5-HT7 receptors in transfected HeLa
cells [91]. Caveolin-1, a cholesterol-binding protein constitutive of a
subtype of lipid domains (referred to as caveolae), interacts with 5-
HT2A receptors and facilitates the functional coupling between 5-
HT2A and Gq proteins [99]. Moreover, caveolin-1 silencingwith siRNA
caused signiﬁcant reductions of serotonin binding to 5-HT7 receptors
[100]. Taken together, these data suggest that the domain localization
of several (if not all) G protein-coupled serotonin receptors is critical
for ligand binding and/or receptor-mediated signaling. A plausible
interpretation of these ﬁndings is that domain lipids (cholesterol,
sphingomyelin, GSLs) can bind to these receptors and affect their
conformation, thereby regulating both serotonin binding and G
protein coupling. Despite the scarcity of high-resolution three-
dimensional structures for G protein-coupled receptors [87,101], the
available structural data are highly informative and may make it
possible to determine whether such regulations are consistent with
the topology of G protein-coupled serotonin receptors.
G protein-coupled receptors consist of a bundle of seven
transmembrane alpha helices, with the amino terminus and three
interhelical loops on the extracellular side and three more loops,
together with the carboxyl terminus exposed to the cytoplasm [101].
The ligand binding site of serotonin receptors is located within the
membrane, so that the amino acid residues involved in the interaction
with serotonin belong to transmembrane helices [102]. This is of
primary importance because such membrane-embedded binding
sites might be accessible only to molecules (serotonin and/or
agonists) that accumulate in the surrounding lipids, as recently
studied by nuclear magnetic resonance spectroscopy [103]. This
further underscores the crucial role of lipid domains as primary
targets for serotonin in the post-synaptic membrane. Once bound to
the receptor, serotonin induces a conformational change which
propagates through the transmembrane domains, and eventually
reaches the second and third intracellular (cytoplasmic) domains
which bind to and activate the G proteins. A conserved motif of three
amino acid residues, referred to as the DRY motif (Asp-Arg-Tyr),
located at the bottom of the third transmembrane domain, has been
shown to play a key role in the switch that activates G proteins upon
serotonin binding to the receptor [102]. Overall, these data suggest
that the regions of the 5-HT1A receptor encompassing the second and
third transmembrane domains and the second intracellular loop form
a coordinated unit which includes important residues involved in
serotonin binding (Asp82 and Asp116) and in signal transduction
(Asp133, Arg134, Tyr135) (Fig. 5). The next issue to resolve is whether
this regulatory cassette contains speciﬁc binding sites for cholesterol
and/or sphingolipids, which could account for the regulatory activity
of these lipids on receptor function.
5.4. Cholesterol binding sites on G protein-coupled serotonin receptors
Since membrane cholesterol is required for the function of several
G protein-coupled receptors [72], it was logical to look for speciﬁc
cholesterol binding sites in serotonin receptors belonging to this
family. Recently, Hanson et al. have identiﬁed a cholesterol binding
pocket in the crystal structure of the β2-adrenergic receptor [104].
This consensus cholesterol motif is highly conserved among G
protein-coupled receptors. Thus, it was possible to delineate a
cholesterol binding domain in the 5-HT1A receptor by homologywith the amino acid sequence of the β2-adrenergic receptor [81]. The
cholesterol binding motif identiﬁed in 5-HT1A by these means
includes Tyr73 in the second transmembrane helix (Fig. 5) and
Ile157 and Trp161 in the fourth one. This topology is consistent with a
regulation of serotonin binding through speciﬁc cholesterol–receptor
interactions. In particular, it is highly signiﬁcant that the same
transmembrane domain (TM2) contains amino acid residues that are
critical for interactions with both cholesterol (Tyr73) and serotonin
(Asp82). This further strengthens our hypothesis that the regions of
the 5-HT1A receptor encompassing the second and third transmem-
brane domains, as well as the second intracellular domain, form a
regulatory cassette allowing the coordinated control of the receptor
by serotonin and by membrane lipids (Fig. 5).
Since cholesterol might regulate the function of most G protein-
coupled serotonin receptors, we searched for a similar cholesterol
binding pocket in the other serotonin receptors (except for 5-HT3
which is not coupled to G proteins and has a distinct membrane
topology). As shown in the amino acid alignments of Fig. 6, the
cholesterol binding motif is well conserved among the different
serotonin receptors coupled to G proteins. Indeed, an aromatic residue
(Tyr or Phe) at the position equivalent to 73 (for 5-HT1A) is found in
all the receptors studied, except for 5-HT5A (Asn). Moreover, the Trp
residue at position 161 is fully conserved, whereas Ile157 is present in
more than 80% of the sequences. Despite someminor variations in the
region of the motif, our data suggest that all these receptors share a
speciﬁc, non-annular binding site for cholesterol, as previously shown
for 5-HT1A [81]. Most importantly, these ﬁndings give a biochemical
explanation for the regulatory effects of cholesterol on the activity of
5-HT1A and related G protein-coupled protein receptors. Mutagenesis
studies focused on the amino acid residues of this conserved
cholesterol binding site will help to validate this attractive model.
Fig. 6. Alignment of the putative cholesterol binding domain in the family of G protein-
coupled serotonin receptors. The cholesterol binding motif has been characterized by
Paila et al. in the 5-HT1A amino acid sequence in various animal species [81], by
homology with the cholesterol consensus motif identiﬁed in the structure of the β2-
adrenergic receptor [104]. The multiple alignments were performed with ClustalW,
using the 5-HT1A sequence as reference. The characters in the consensus sequence
correspond to the frequency of the amino acid at the indicated position: “.” N20%, “:”
N40%, “+” N 60%, “⁎” N80%, and the amino acid letter if 100%.
Fig. 7. The extracellular (EC), transmembrane (TM) and MA domains of the AChR are
shown in a lipid bilayer. The 3D structure is based on cryoelectron microscopy data of
the AChR at 4 Å resolution [131] and served as the starting conditions in a recent
molecular dynamics study [191]. The receptor protein is embedded in a DPPC lipid
bilayer (phospholipid acyl chains shown in green) and water molecules (red). Only
three subunits (color-coded in red, blue and yellow) are displayed for clarity. The
innermost ring of M2 helices is rendered with electrostatic potential surface to
highlight the pore shape [191].
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coupled serotonin receptors [92,100], it would be interesting to look
for potential sphingolipid binding sites around the second and third
transmembrane domains of these receptors, for instance in the second
extracellular domain.
5.5. The 5-HT3 receptor: an ionotropic ligand-gated ion channel
The 5-HT3 receptor is the only serotonin receptor subtype whose
activity is not mediated via G proteins. Instead it is an ionotropic
ligand-gated ion channel (LGIC) belonging to the Cys-loop superfam-
ily of LGICs, that also includes the nicotinic acetylcholine receptor
(AChR), the anion-selective GABA type A (GABAA) receptor, and the
glycine receptor [105]. The LGIC superfamily comprises several
families of evolutionarily related neurotransmitter receptor proteins
coded by a few hundreds of genes so far identiﬁed. LGICs mediate
excitatory and inhibitory chemical transmission.
The common structure of the receptors belonging to the LGIC
superfamily is a regular arrangement of ﬁve pseudo-symmetrically
subunits surrounding a central ion-conducting pore Each subunit is
composed of an extracellular domain, which contains the ligand
binding domain, a transmembrane region made up of four mem-
brane-spanning α-helices (M1–M4) and an intracellular domain [87].
The binding site is formed at the interface of two adjacent subunits by
the convergence of three loops (A–C) from one subunit and three β-
strands (D–F) from the adjacent (or complementary) subunit. The M2
helix from each subunit lines the pore and contains regions
responsible for channel gating and ion selectivity. In the case of the
ionotropic 5-HT3 receptor, this pore is predominantly sodium- and
potassium-selective, and its opening results in a rapidly activating and
then desensitising inward current [106]. In both stably transfected
human embryonic and neuroblastoma cells, the 5-HT3A receptor was
detected in lipid domains [107]. Thus the functionality of this type of
5-HT3 receptor, like most other serotonin receptors, seems to depend
upon speciﬁc interactions with surrounding raft lipids. Particularly
interesting is the ﬁnding that various antidepressant and antipsy-
chotic drug co-localize with this receptor in lipid microdomains [107].
This further strengthens the idea that raft lipids (especially GSLs) are
accessory binding sites for the natural and/or synthetic ligands of
numerous neurotransmitter receptors (Fig. 3). It is not known
whether cholesterol and/or sphingolipids can directly bind to and/
or regulate the activity of the 5-HT3 ligand-gated channel. However,given the structural homology between 5-HT3 receptor and the AChR,
this would be far from illogical (see below).
6. Nicotinic acetylcholine receptors
6.1. Overall structure and lipid contacts of the multimeric protein
Several genes coding for AChR subunits have been characterized in
central and peripheral nervous systems. They exhibit amino acid
sequence homology and presumably higher-order structural motifs.
Within the LGIC superfamily, the AChR and the 5-HT3 receptor
comprise two families of cation-selective channels, whereas glycine
and gamma aminobutyric acid type A (GABAA) receptors are anion-
selective channels. Members of this superfamily are also known as
Cys-loop receptors because in their amino-terminal all their subunits
contain extracellular halves of a pair of disulphide-bonded cysteines
separated by only 13 residues. Like several other transmembrane (TM)
proteins of the large ligand-gated ion channel superfamily, the AChR
exposes about half of its mass to the extracellular space, about one
third lies in the intracellular compartment, and each AChR subunit
contributes with four hydrophobic segments, 20–30 amino acids in
length, the M1–M4 membrane-spanning or TM segments (Fig. 7). Of
these, the M2 segment from each subunit contributes structurally to
the formation of the ion channel proper. M4 is the segment most
exposed to the bilayer lipid. M1 and M3 effectively incorporate
membrane-partitioning photoactivatable probes and are also exposed,
albeit less than M4, to the lipid phase. We have proposed that the
extensive interface between the protein and lipidmoieties, comprising
both the lipid-exposed TMportions of the AChR protein and the AChR-
vicinal lipid [108,109], constitutes a functional domain of the AChR.
From a structural point of view, the lipid moiety of this interface
constitutes the lipid belt (“shell,” “annulus,” “boundary,” “AChR-
vicinal”) region, that is the lipid moiety in the immediate perimeter of
the AChR protein, discovered using electron spin resonance (ESR)
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lipid selectivity and stoichiometry [111–116]. Fig. 8 depicts a
schematic representation of the AChR macromolecule in the lipid
bilayer, highlighting (in red) the innermost shell of lipid molecules
constituting the annular region.
Early studies from the group of McNamee [117,118] showed that
the overall phase state of the membrane was also important for
receptor function: the capacity of reconstituted AChR to translocate
ions in vitro was found to be sensitive to the bulk physical properties
of the host membrane. The above-mentioned physical studies on
AChR-rich membranes [110,116,119] made apparent the occurrence
of two distinct signals in ESR spectra of native and reconstituted
membranes containing the receptor protein at relatively high or low
concentrations: one signal corresponded to the bulk membrane lipid
and the other was interpreted as stemming from the protein-
immobilized lipid. These direct interactions between protein and
lipid moieties were observed with fatty acids, phospholipids and
sterols in the native membrane environment. Rousselet et al. [119]
found immobilization with fatty acids but not with phospholipids.
Ellena et al. [114] conﬁrmed the earlier ﬁndings using reconstituted
AChR. This series of studies from different laboratories demonstrated
that shell or annular protein-vicinal lipids are relatively immobile
with respect to the rest of the membrane lipids and pointed to the
existence of phase lateral heterogeneity in membrane lipids much
earlier than the concept of “rafts” came into use.
Functional studies contributed to understanding the role of lipids
in AChR ion permeability. The need to include sterols and certain
phospholipids to preserve this property of the AChR in reconstituted
systems was subsequently demonstrated [120]. The relative contribu-Fig. 8. The AChR and its lipid domain. The bulk lipid region is depicted as green and
yellow phospholipid molecules. The red spheres immediately adjacent to the AChR
molecules represent the polar head regions of the phospholipids in the ﬁrst-shell (“belt
layer,” “annular”) region [78,110,150,156]. Unlike the vast majority of individual
proteins in cell-surface membranes (“iceberg-like embedded proteins in a sea of lipid”),
the AChR molecules form tightly packed two-dimensional arrays in the postsynaptic
membrane, in which lipid molecules ﬁll in the interstices. Only three to four
phospholipid shells of bulk lipid separate the protein-vicinal ﬁrst shell from an
homologous, adjacent one surrounding a neighbour AChR protein. Both bulk and shell
lipids in the membrane are in the liquid-ordered (lo) phase, with decreasing polarity
towards the protein molecule [152]. That is, the protein-vicinal lipid-belt region is more
ordered than the bulk, bilayer lipid, and yet the two lipid regions form a continuum
from the physico-chemical point of view. The protein-vicinal ﬁrst-shell lipid is
relatively immobilized with respect to motions both around and perpendicular to the
long molecular axes of the lipid molecules, respectively, with rotational correlation
times about 50–100 times longer than is typically found with ﬂuid bilayer lipid
[78,110,112,116,150,156]. Notice that even the ﬁrst-shell lipid is quite distant from the
ion pore in the receptor protein, as made apparent in the vertically sectioned AChR
molecule depicted on the right. Yet mutations in the outermost ring, the TM4 region
[108] have a profound inﬂuence on AChR ion channel function [109].tions of phospholipid and sterol were established in various studies in
vitro [121–123] and the minimal number of lipid molecules (∼45) per
AChR was ascertained in ESR experiments [114,124]. AChR-vicinal
lipids appeared to be an inherently relevant environmental feature of
the AChR native membrane, but the nature of the interaction between
protein and lipid moieties was still obscure, as were the possible
functional implications proposed in early work [110].
Electron microscopy experiments over 20 years ago already
indicated that about half the mass of the AChR protein protrudes into
the extracellular space, about 30% corresponds to TM domains, and the
remainder is in the cytoplasmic compartment [125–128]. The agonist
recognition domains of the AChR were also located in the extracellular
portion of the macromolecule (ref. [126], and see review in [129]) at a
distance of about 25 Å from the apex of the AChR [130] and about 30 Å
from the membrane surface [131–133]. The search for functionally
relevant regions of the protein based on this «topographical anatomy»
of the AChR protein was thus targeted to the TM domains.
Site-directed mutagenesis of the AChR combined with patch-
clamp electrophysiological and photoafﬁnity labeling experiments
with noncompetitive channel blockers support the notion that one of
the TM AChR regions, the M2 domain, lines the walls of the pore. The
data are also indicative of α-helical periodicity in the residues
exposed to the lumen of the AChR channel [134]. NMR studies of
the M2 segment of the δ subunit indicate that this domain is inserted
in the bilayer at an angle of 12° relative to the membrane normal, in a
totally α-helical conﬁguration [135]. Analogously, a synthetic peptide
corresponding to the Torpedo αM2 segment in organic solvents also
adopts a totally α-helical conﬁguration [136]. Cryoelectron micro-
scope data conﬁrmed thatM2 forms the innermost ring of membrane-
spanning segments, isolated from membrane lipids [137,138].
During the 1990s, cryoelectron microscopy fell short of revealing
the structure of the other putative TM domains (M1, M3 and M4). In
fact, a large portion of this AChR region was postulated to be arranged
in the form of a β-barrel outside the central rim of M2 channel-
forming rods [139]. This interpretation contrasted with photoafﬁnity
labeling studies, in which the observed periodicity of the lipid-
exposed residues in M4 and M3 was consistent with an α-helical
pattern [140–142], and with deuterium-exchange Fourier transform
infrared spectroscopy studies indicating a predominantly α-helical
structure in the AChR TM region [143]. In addition, secondary
structure analysis (CD and Fourier transform infrared spectroscopy)
of isolated and lipid-reconstituted TM AChR peptides indicated α-
helical structure for M2, M3, and M4 segments [144]. Furthermore, a
synthetic peptide corresponding to the αM3 segment of Torpedo
AChR exhibited a totally α-helical structure by two-dimensional 1H-
NMR spectroscopy [145]; NMR studies of a synthetic γM4 peptide are
also compatible with an α-helical secondary structure [146].
Considerable advance in deﬁning the structure of the AChR at
atomic resolution [147] resulted from crystallographic studies of a
water-soluble ACh-binding protein from a snail. The structure of this
protein, highly homologous to the water-soluble extracellular domain
of the AChR protein proper [147], provided the ﬁrst truly high-
resolution data of the region of the AChR involved in agonist
recognition, the ﬁrst step in the cascade leading to channel opening.
More recent work has resulted in the crystallization of the actual
water-soluble extracellular domain of the mouse AChR α-subunit
bound to the competitive cholinergic antagonist α-bungarotoxin. The
crystal structure was solved at 1.94 Å resolution [148].
6.2. The lipid shell surrounding the AChR outer ring is different from the
bulk lipid in lipid contents and dynamics
The cryo-electron microscopy data of Unwin and coworkers
[137–139] at 4 Å resolution provided inspiring insights into the
structure of the AChR and particularly relevant to the subject of this
review, the electron microscopy data revealed interesting features
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occurrence of three concentric rings in the AChR region has been
described [108]: (a) an inner ring exclusively formed by ﬁve M2
segments, corresponding to the walls of the AChR ion pore, which
have no contact with the membrane lipid; (b) a middle ring, formed
by 10 helices corresponding to the M1 and M3 TM segments. This
middle ring is separated from the inner ﬁve-member ring of M2s,
and its outer face is exposed to lipids and also to (c) the outermost
ring, consisting of ﬁve M4 segments.
6.2.1. Composition and relative afﬁnities in the lipid shell
The FRET studies using the SM ﬂuorescent derivative also yielded
information on the relative afﬁnity of the SM derivative for the AChR
protein. Thus, Py-SM exhibited a moderate-to-low selectivity for the
protein-vicinal lipid domain, with a calculated relative afﬁnity
Kr@0.55 [149]. This ﬁgure should be added to the list of known
selectivities of other lipids for the AChR calculated from early ESR
experiments: PS (0.7), PC (1.0), PE (1.1), PA (2.7) and stearic acid
(4.1) by Ellena and coworkers [114], and to those determined by us
more recently, also using ESR techniques [150], allowing a
classiﬁcation of lipids according to their selectivity for the AChR
protein. The study by Mantipragada et al. [150] provided the ﬁrst
detailed description of the dynamic composition of “ﬁrst-shell” lipids
in the belt region surrounding a receptor protein. AChR-vicinal lipids
fall into three categories: (a) a high speciﬁcity group, constituted by
fatty acids like stearic acid, cardiolipin and phosphatidylinositols
[150–151], androstanol [116–151], and phosphatidic acid [114]; (b)
an intermediate group, made up of SM [149], PS and PG [150], and
(c) a moderate-to-low speciﬁcity group, where we ﬁnd PC, PE, and
the gangliosides GD1b, GM1, GM2 and GM3 [150].
It is interesting to note that owing to the high-packing density of
AChR molecules in the postsynaptic membrane, only three to four
phospholipid layers of “bulk” lipid separate the protein-vicinal ﬁrst
layer from the nearest-neighbour ﬁrst-layer lipid surrounding an
adjacent AChR protein [109]. In Torpedo receptor-rich native mem-
branes prepared from electrocytes, all lipids in the membrane are in
the liquid-ordered (lo) phase, with decreasing polarity towards the
AChR protein molecules [152]. This is because the protein-vicinal
lipid-belt region is more rigid and ordered than the bulk bilayer lipid,
as determined by Laurdan GP measurements using FRET [152,153].
However, the receptor-vicinal and the bulk lipid regions form a single,
liquid-ordered phase from the physico-chemical point of view.
6.2.2. Dynamics of the lipid shell
The mobility at the lipid shell surrounding the AChR protein (the
AChR-vicinal lipid, see Fig. 8) is reduced relative to that of the bulk
membrane lipid, giving rise to a two-component ESR spectrum from
which the number and selectivity of the lipids at the lipid–protein
interface may be quantitated (see e.g. [116]). The protein-induced
restrictions on the mobility of lipids exhibits selectivity. Spin-labeled
fatty acids and anthracene [118] phospholipids [116], steroids and
phosphatidic acid (PA) exhibit higher selectivity than other kinds of
lipid [114,119]. This permitted the formulation of a hypothesis on the
possible functional implications of the immobilization and the inherent
topographical relationship (see Fig. 8). The crucial relationship between
lipid and AChR protein became apparent in ion-ﬂux studies showing
that cholesterol and negatively charged phospholipidswere required to
support the gating activity of the AChR [121,122,154] whereas fatty
acids blocked the ion-ﬂux response [155]. The latter was interpreted as
the perturbation of the interaction between AChR and cholesterol/
negatively charged phospholipids.
How ‘rigid’ is the lipid surrounding the AChR protein relative to the
ﬂuid bilayer (‘bulk’) lipid? The protein-vicinal lipid is relatively
immobilized with respect to motions both around and perpendicular
to the long molecular axes of the lipid molecules, i.e., with rotational
correlation times ∼50–100 times longer than is typically found withﬂuid bilayer lipid [110]. The protein-vicinal lipid also exhibits a lower
degree of penetration of water molecules, thus rendering it less polar
than the bulk bilayer lipid [152,153]. Another dynamic aspect that
characterizes the two lipid regions is the relatively high exchange
between the two moieties: although the AChR-vicinal lipid is
expected to have a lateral diffusion coefﬁcient 50–100 times slower
than that of the ﬂuid bilayer lipid, i.e. ∼105 s-1 [110], the lipid
exchange process between the AChR-vicinal lipid and the bulk lipid
exhibits rates in the order of 1–5×108 s-1. Lipid species displaying
selectivity for the AChR protein (see previous section) spend longer
on average in the immediate vicinity of the protein; hence they are
concentrated relative to those lipids exhibiting little or no selectivity.
In systems where the selectivity of the lipid for the protein is changed
by varying the pH or the ionic strength, it has been shown that the on-
rate remains constant, whereas the off-rates reﬂect the speciﬁcity of a
given lipid, which is independent of the lipid–protein ratio [156] (see
also Fig. 8).
6.3. Cholesterol, sphingomyelins and the AChR
Here we shall discuss some structural aspects of the cholesterol–
AChR interactions. The reader is referred to a recent topical review for
the treatment of the functional modulation exerted by cholesterol on
the ion channel properties and on the endocytic and exocytic
trafﬁcking of the receptor protein [73].
Early studies reported that cholesterol increased the α-helix
content of the AChR. The sterol was postulated to stabilize AChR
structure by packing its rigid planar ring into grooves of transmem-
brane helices [157], as is further discussed in other sections of this
review. Circular dichroism spectroscopy [158], Raman spectroscopy
[159] and 1H/3H exchange studies [160] detected no great differences
in structure or solvent accessibility between the two main conforma-
tional states of the AChR, i.e., that occurring in the absence of agonist (
the “resting” state) and the thermodynamically preferred conforma-
tion observed upon prolonged exposure to the agonist (the “desensi-
tized” state), respectively. The accessibility of AChR ﬂuorophores to
membrane probes between resting and desensitized forms of the
AChR is also different [161], as is the accessibility of residues near the
ligand recognition site [162] and the transmembrane domains [163].
Castresana et al. [164] reported that the helical content of the AChR
was not affected by addition of agonist, whereas the proportion of β-
structure decreased to 24% concomitant with an increase in
unordered structure. Lack of cholesterol in an asolectin reconstitution
system produced an increase of disordered structure in Torpedo
marmorata AChR [165]. Addition of exogenous cholesterol resulted in
restoration of the proportion of ordered structures in asolectin
liposomes but not in liposomes prepared from egg phosphatidylcho-
lines, leading these authors to suggest that a component other than PC
is needed for the restoration of AChR structure in the presence of
cholesterol. Using Fourier transform infrared spectroscopy, Méthot et
al. [166] found 39% α-helix, 35% β-sheet, 20% random coil and 6% turn
in Torpedo californica AChR reconstituted in dioleoyl-phosphatidyl-
choline, dioleoyl-phosphatidic acid and cholesterol (3:1:1). In another
series of studies also using Fourier transform infrared spectroscopy,
Görne-Tschelnokow et al. [167] concluded from their data that the
transmembrane region of the AChR contains 40% β-sheet plus turn
structure. With the same technique, Baezinger and Méthot [168]
produced experimental evidence supporting an all-helical model of
the AChR transmembrane region. Thus, the relative proportions of
helical structure found in these studies were in general agreement
with that expected for the 25 AChR helices embedded in the
membrane bilayer; that is, the experimental data reveal that the
AChR exhibits sufﬁcient α-helical content to account for four-helical
transmembrane segments in each subunit and still provide some
helical content to the extracellular region.
Fig. 9. Examples of sphingolipid binding domains. (A) SBD in the alpha chain of the
acetylcholine receptor (chain A) retrieved from the Protein DataBank (PDB) entry 2BG9
[131]. This domain is located at the boundary between the extracellular (EC) and
transmembrane (TM) regions of the receptor shown in Fig. 7. The aromatic residues
(F170 and W176) are buried in the three-dimensional structure of the receptor. The
charged residues (E172, E175, and K179) are located on the protein/membrane
interface, consistent with an interaction with surrounding membrane lipids, especially
sphingomyelin. (B) The prototype SBD (and the ﬁrst ever characterized): the V3 loop of
HIV-1 gp120. In this case, both the aromatic F20 and the basic R18 residues are
accessible to sphingolipids (sphingomyelin and GalCer).
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infrared spectroscopy studies of Baezinger's group [168,169] indicat-
ed that 1H/2H exchange kinetics was slower in the presence of
dioleoyl-phosphatidic acid or cholesterol, suggesting that the lipid
environment modulates the conformational dynamics of the mem-
brane-embedded peptide hydrogens that exchange with deuterium.
No great changes in secondary structure were observed in the
presence of cholesterol also using Fourier transform infrared
spectroscopy [170]. An early study using this technique in combina-
tion with radioactive ion-ﬂux experiments [171] suggested that lipid
mixtures containing saturated phosphatidylcholine, anionic phos-
pholipid (phosphatidic acid) and cholesterol stabilize the receptor in
the resting state and allow agonist-induced state transitions. All in all,
the wealth of evidence points to the need for cholesterol in the
membrane milieu of the AChR for maintaining its correct structure
and the ability to undergo conformational transitions.
The other class of lipid that is present in ordered domains in the
membranes is that of sphingolipids, which account for about 5% of the
total lipid content of AChR-rich membranes obtained from the
electrocytes of Torpedinidae ﬁsh [172,173]. The topography of
sphingomyelin (SM) in the Torpedo AChR-rich membrane has been
the subject of cytochemical and biophysical studies [149]. The afﬁnity
of SM for the AChR protein has been established using ﬂuorescence
techniques: the lipid exhibits only moderate-to-low afﬁnity for the
receptor protein [149]. More recently, a role for SM in AChR trafﬁcking
has been disclosed; biochemical and ﬂuorescence microscopy studies
showed that inhibition of sphingolipid biosynthesis resulted in the
accumulation of unassembled AChR oligomers in the endoplasmic
reticulum. These experimental observations led to the suggestion that
sphingomyelins could play a “chaperone-like” effect on the AChR
biosynthetic pathway, affecting both the efﬁciency of the assembly
process and subsequent receptor trafﬁcking to the cell surface [70].
7. Conformational effects of sphingolipids: from physical
chemistry to physiology
7.1. The sphingolipid binding domain
The proposal that protein–glycolipid interactions follow a univer-
sal scheme based on a unique biochemical mechanism has emerged
from a comprehensive molecular modelling approach combined with
thorough physicochemical studies of peptide–glycolipid and/or
protein–glycolipid interactions [174–176]. This is the concept of the
glycolipid binding domain, or, more generally, of the sphingolipid
binding domain (SBD), which has been extensively reviewed
[2,5,177–179]. Brieﬂy, the domain generally consists of a hairpin
loop with speciﬁc amino acid requirements. Aromatic residues stack
onto the sugars rings of GSLs (CH–Pi stacking), whereas charged
residues can form electrostatic bonds with sphingomyelin. An SBD
displaying a single aromatic residue, but no charged residue, can
efﬁciently bind to neutral GSLs [180]. The simultaneous presence of
aromatic and basic residues extends the GSL repertory to gangliosides
[181,182]. Finally, charged residues (either acidic or basic) are
commonly found in synthetic peptides that bind to sphingomyelin
[175,183].
In the case of membrane proteins, SBD are generally located in
extracellular regions close to the polar–apolar interface of the
membrane, so that the side chains of the amino acid residues of the
domain can bind to the polar headgroup of the sphingolipid [5].
Indeed, in the three-dimensional structure of the nicotinic acetylcho-
line receptor alpha chain, an SBD can be predicted at the periphery of
the subunit, in contact with membrane lipids (Fig. 9A). This SBD
contains two aromatic residues whose side chains are oriented
toward the interior of the loop and contribute to its stabilization. In
contrast, two Glu and one Lys residues, fully accessible for membrane
lipids, can theoretically interact with sphingomyelin. This domaincould be involved in the regulation of the conformation and trafﬁcking
of the AChR [70]. For comparison, we also showed the structure of the
ﬁrst SBD ever characterized, i.e., the V3 loop of the HIV-1 surface
envelope glycoprotein gp120 (Fig. 9B). This SBD recognizes both
GalCer and sphingomyelin [2] which is consistent with the accessi-
bility of Phe and Arg side chains.
Functional sphingolipid and/or glycolipid binding domains have
been identiﬁed in a wide range of proteins, including Fas/CD95,
class I MHC, EGF and PDGF receptor, Thy-1, prominin (CD133),
intestinal alkaline phosphatase, the glucose transporter GLUT-1,
Helicobacter pylori adhesin, shiga and botulinum toxins, hepatitis C
virus non structural protein, as well as various amyloid proteins
[2,5,177,179–181,183–184]. All these SBD have been successfully
predicted by either sequence or structure similarity searches using
the HIV-1 gp120 V3 loop as template. Finally, a ﬂuorescent probe
based on the SBD identiﬁed in the beta-amyloid peptide [175] has
been shown to speciﬁcally interact with sphingolipids and choles-
terol-dependent raft domains on live neural cells, further demon-
strating the robustness of the SBD concept [185].
7.2. Molecular mechanisms: CH–Pi interactions and GSL-associated
chaperone activity
As discussed above, it has been shown that sphingolipids are
necessary for the export of the AChR in the early secretory pathway
[70]. In this case, it is likely that the sphingolipids (especially
sphingomyelin) have a chaperone effect at early stages of the
acetylcholine receptor biosynthetic pathway. A similar effect of
sphingolipids has been demonstrated in the case of the cellular
isoform of the prion protein [186], which also contains a sphingolipid
binding domain [175,179].
What are the molecular mechanisms behind the chaperone
activity of sphingolipids? Though this issue has not yet been fully
resolved, some interesting progress has been made by studying the
molecular mechanisms controlling the interaction of sugars with
aromatic compounds [83]. In solution, an aromatic ring tends to stack
onto another aromatic ring to avoid the thermodynamically unfa-
vourable contacts with water molecules. The resulting Pi–Pi stacking
interaction contributes to major biological functions, such as the
stability of the DNA double helix and protein folding [187]. However,
it has recently been shown that the self-aggregation of adenine in
water solution, which results from a Pi–Pi stacking-driven process,
can be abrogated by free sugars, the most active being beta-galactose
[83]. Beta-galactose is unique among hexoses because its pyranic
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[83,176]. The apolar surface of galactose provides a perfect comple-
mentary surface for the aromatic cycle, onto which it readily binds
through a CH–Pi stacking interaction, with the CH groups of galactose
facing the delocalized Pi electronic cloud of the aromatic ring as
shown in Fig. 10 for toluene [176] and phenylalanine. In both cases,
water molecules are excluded from the space between the stacked
cycles and rejected at the periphery of the complex. This entropic-
driven process further stabilizes the sugar-aromatic complex.
Now, what happens if we extrapolate this physical chemistry
property of sugar-aromatic systems to GSL–protein duets? The side
chains of aromatic amino acids tend to be protected from the solvent
so that they are generally buried in the three-dimensional structure of
the protein. This feature is so frequent that when the aromatic side
chain of a Trp residue is exposed on the surface of a protein, it
generally indicates a ligand binding site [188]. By providing a
complementary surface for accessible aromatic side chains, the
glycone part of membrane GSLs may interfere with the natural
propensity of aromatic cycles to bury themselves in apolar crevices of
the protein. By doing this, the GSL induces a signiﬁcant conforma-
tional rearrangement which can be considered as a chaperone-like
effect [189]. From a physical chemistry point of view, the intramo-
lecular Pi–Pi stacking interactions between aromatic residues of the
protein are substituted by intermolecular (GSL–protein) CH–Pi
stacking interactions. This ‘stacking exchange’ between Pi–Pi and
CH–Pi is possible at minimal energy cost because these interactions
share the same geometry [177]. The consequence is a conformational
effect which may, in the speciﬁc case of a neurotransmitter receptor,
affect the ligand binding pocket and/or the coupling machinery to the
effector functions (protein G or channel activation). Conceptually,Fig. 10. The CH–Pi stacking interaction. Upper panels: Molecular modelling of a toluene–gala
between toluene (Tol) and β-D-galactose (Gal) was ﬁrst minimized with the Polak-Ribiere alg
of 216 water molecules. Molecular dynamics simulations with the MM+ force ﬁeld were the
and B) are shown, along with the 216 water molecules. Lower panels: Molecular model
orientations, viewed from Phe (C), proﬁle (D) and from Gal (E). Note the near-perfect geome
modelling simulations were performed using the same conditions as for the toluene–galacto
the models.similar effects could be obtained through electrostatic interactions
between proteins and charged sphingolipids such as sphingomyelin
[70,175].
7.3. Fine tuning of GSL conformation by cholesterol
Basically, the binding of cholesterol to the transmembrane helices
of receptors could also produce important conformational effects on
these proteins [81]. This certainly contributes to the regulatory effects
cholesterol exerts on many receptors [71–73,96]. The molecular
mechanisms involved in the association of cholesterol with trans-
membrane helices have not been fully deciphered, but aromatic
residues seem to play an important role (Fig. 6). Indeed, aromatic
cycles have the potency to stack onto the rigid cycles of cholesterol,
thereby forming stabilizing CH–Pi interactions. In addition, themethyl
groups of the beta side of cholesterol (Fig. 2) can insert into local
crevices of the transmembrane helices which are delineated by the
branched side chains of aliphatic amino acid residues such as the
frequently encountered Ile and Val. This suggests that, if the beta face
of cholesterol interacts with a transmembrane helix, its smooth alpha
side can interact with a sphingolipid (Fig. 11). The possibility
therefore exists of forming a ternary complex in which cholesterol
interacts simultaneously with one of the transmembrane domains of
the receptor and with a GSL. The glycone part of the GSL protrudes
from the membrane and its orientation is largely determined by the
OH group of cholesterol [5]. In other words, cholesterol can
simultaneously control the conformation of the GSL and the
conformation of the receptor. If one considers that the GSL itself can
bind to the receptor and affect its conformation, it becomes evident
that we are facing a complex network of molecular crosstalk betweenctose complex in water (modiﬁed from ref. [176]). The geometry of a molecular complex
orithm. Themolecules were then introduced in a periodic box of 18.7 Å3 in the presence
n conducted for 10 ps with Hyperchem 7 software. Two distinct views of the complex (A
ling of galactose–phenylalanine (Gal–Phe) interactions in water under three distinct
tric superposition of both cycles forming the CH–Pi stacking interaction. The molecular
se complex. The surrounding water molecules were not shown to improve the clarity of
Fig. 11. Ternary complex beween a transmembrane helix, cholesterol and a GSL.
Cholesterol (chol) is in green, with its smooth alpha face interacting with the ceramide
part of the GSL (on the right). A representative transmembrane domain (TM) with Ile
and Val side chains interacts with the beta face of cholesterol (yellow surface). Note
how the polar head of the GSL has adapted its shape to the TM–cholesterol complex.
This indicates that each partner of the complex might inﬂuence the conformation of the
others.
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offered by this molecular interplay would allow a ﬁne tuning of
receptor trafﬁcking, sensitivity to neurotransmitters, and functional
coupling to effector mechanisms. Deciphering this molecular lan-
guage will be a hard but fascinating task in the coming years.
8. Conclusions and perspectives
Several lessons can be drawn from this overview. Starting from a
list of clearly identiﬁed biochemical mechanisms involving speciﬁc
lipid–protein interactions, we have attempted to shed some light on
their physiological signiﬁcance for neurotransmitter receptor function
with special emphasis on serotonin and acetylcholine receptors,
which include two main types of receptors: G protein-coupled
proteins with seven transmembrane domains, and multimeric
assemblies of protein subunits forming a ligand-gated ionic channel.
Like all other transmembrane proteins, these receptors are sur-
rounded by a shell of lipids which may primarily affect their
trafﬁcking between raft and non-raft fractions of the plasma
membrane. In addition, these receptors can speciﬁcally interact with
cholesterol and sphingolipids through typical binding sites located in
both the transmembrane helices and the extracellular loops. These
lipidic ligands modify the conformation of the receptor, affecting both
neurotransmitter binding and signal transducing functions.
Biochemical fact 1: Neurotransmitters bind to GSLs.
Physiological consequence: Following release from synaptic vesi-
cles, neurotransmitters are attracted by GSLs (chieﬂy gangliosides) in
the post-synaptic membrane. This has two main consequences: (i)
concentration of neurotransmitter monomers in GSL-enriched areas
of the membrane, where neurotransmitter receptors are also
concentrated; (ii) GSL-assisted delivery of the neurotransmitter to
its receptor, according to the two-receptor model developed by C.
Montecucco for neural toxins [47,48]. In some instances, the GSL couldaffect the conformation of the neurotransmitter, thereby facilitating
the preselection a receptor subtype. This could be particularly
important for serotonin, which can adopt distinct conformations
and interacts with several distinct receptors.
Biochemical fact 2: Some neurotransmitter receptors are associated
with lipid domains.
Physiological consequence: Although not formally demonstrated for
all neurotransmitter receptors, the available data strongly suggest
that lipid domains are indeed the regions of the plasma membrane
where some receptors act [190]. This is the case for G protein-coupled
receptors which, upon binding of the neurotransmitter, interact with
and activate G proteins that are themselves present in lipid domains.
In this respect, lipid domains allow the functional coupling between
the two leaﬂets of the plasma membrane, the extracellular one which
captures the messengers, and the intracellular one which triggers G
protein action. The other reason is that cholesterol and sphingolipids,
which exert important regulatory effects on these receptors, are
typical raft lipids. Cholesterol and sphingolipids might be particularly
important for ligand-gated ionic channels whose subunits have to
assemble and cooperate before and upon neurotransmitter binding
(see below).
Biochemical fact 3: Cholesterol binds to some neurotransmitter
receptors.
Physiological consequence: The transmembrane domains of neuro-
transmitter receptors have a major role in both the acquisition and
dynamics of the active three-dimensional structure of the receptors.
In the case of G protein-coupled serotonin receptors, the binding
pocket is located inside the membrane, mainly between the 2nd and
3rd transmembrane helices. A cholesterol binding motif with
conserved amino acid residues has been characterized in the vicinity
of the ligand binding pocket. Correspondingly, cholesterol has a major
effect on ligand binding. Moreover, the transmembrane domains are
those that link the ligand binding pocket to the switch responsible for
signal transduction triggering, so cholesterol can also directly control
this process. Cholesterol binding sites have not been fully identiﬁed in
the case of the AChR, but ligand binding, stability at the membrane
and trafﬁcking to the cell surface are all dependent on normal
cholesterol levels in the cell. Finally, one should be aware that
cholesterol is a bifacial molecule with two topologically distinct
surfaces, one rough and the other smooth. This allows cholesterol to
interact at the same time with a transmembrane domain of the
receptor and with a GSL, thereby inducing conformational adjust-
ments on both partners (the GSL and the receptor).
Biochemical fact 4: Sphingolipids bind to neurotransmitter
receptors.
Physiological consequence: This is perhaps the main mechanism of
regulation of receptor function by membrane lipids, and certainly
one essential function of brain sphingolipids. The extracellular
regions of the receptors can display structurally related but
functionally speciﬁc SBDs for neutral, cationic, and/or acid sphingo-
lipids. These sphingolipids induce profound conformational changes
in these receptors, which can affect both ligand binding and
signalling pathways. The molecular mechanisms involved in this
chaperone effect of sphingolipids has remained elusive for many
years, but recent data obtained from physical chemistry studies have
emphasized the importance of CH–Pi stacking interaction between
GSLs and aromatic side chains of proteins. The conformational effects
of sphingolipids are generally cholesterol-dependent, because cho-
lesterol binds to most sphingolipids and largely determines their
biologically active conformation.
In summary, several decades of research have been necessary to
untangle the skein of a complex network of molecular interactions
between neurotransmitters, their protein receptors, cholesterol and
sphingolipids. Such sophisticated crosstalk between all four distinc-
tive partners may allow a ﬁne biochemical tuning of synaptic
transmission. We surmise that this aspect of synaptic regulation,
2358 J. Fantini, F.J. Barrantes / Biochimica et Biophysica Acta 1788 (2009) 2345–2361involving sphingolipid/cholesterol regulation of neurotransmitter
receptor function, will lead to challenging discoveries in the
neurosciences.
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